Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis

Abroad (travel likely)RecruitingPHASE4

Conditions

Rheumatoid Arthritis (RA) · Rituximab (RTx)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Contact: Study coordinator (Eden SEBBAG, MD) · eden.sebbag@chru-strasbourg.fr · 03 88 12 66 71

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases

Rheumatoid Arthritis (RA) · Psoriatic Arthritis (PsA) · Axial Spondyloarthritis (AxSpA)

Abroad (travel likely)RecruitingPHASE4

Nijmegen, Netherlands · Maastricht, Netherlands

Advanced Therapeutics in Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Abroad (travel likely)RecruitingPHASE4

London, Canada

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Abroad (travel likely)RecruitingPHASE4

Verona, Italy

Medical Device for Sustained Remission in Rheumatoid Arthritis Treated With Biological Therapy

Rheumatoid Arthritis (RA)

Abroad (travel likely)Recruiting

A Coruña, Spain · Alava, Spain